UNSPSC 51141552: Ethylphenacemide or pheneturide

This classification denotes an anticonvulsant agent with the molecular formula C11H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 878CEJ4HGX, chemically known as urea, (2-phenylbutyryl)- but generally known as ethylphenacemide, which bears US NIH Compound Identifier 72060. European Medicines Agency schedules Pheneturide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09760MIG.

The term PHENETURIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules ethylphenacemide in its Anatomical Therapeutic Chemical (ATC) Classification. Ethylphenacemide or pheneturide bears US NLM identifiers UMLS ID C0059837 and NCI Concept Code C72826. SMILES: CCC(C1=CC=CC=C1)C(=O)NC(=O)N.

UNSPSC 51141552 Ethylphenacemide or pheneturide is a Commodity code that in recent state and local procurement activity does not align with its nominal chemical scope. The three recent opportunities tagged to this code show minimal or no connection to ethylphenacemide itself; instead, they reflect procurements for naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. The code shows little relevant recent activity for its stated pharmaceutical chemical product.

When relevant activity does appear under pharmaceutical Commodity codes in state and local procurement, it tends to involve health authorities and state human services agencies acquiring finished drugs, OTC supplies, and pharmacy program services rather than raw chemical intermediates. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) under the Minnesota Department of Administration issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription procurement capabilities. The geographic spread reflects activity across Florida, Texas, Minnesota, and Oregon through state departments and county health entities, though the code itself appears mismatched to the work actually being bought.